Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
10 Health Care Stocks With Whale Alerts In Today's Session
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
21 Stocks to Play a 'Magical Moment' in Healthcare -- Barrons.com
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
Sector Update: Health Care Stocks Retreat Late Afternoon
Morgan Stanley Starts Structure Therapeutics at Overweight
Skye Stock Rallies 22% Following Weight-loss Drug Update
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success
Structure Therapeutics Price Target Announced at $118.00/Share by Morgan Stanley
Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118
Morgan Stanley analyst Terence Flynn initiates coverage on $Structure Therapeutics(GPCR.US)$ with a buy rating, and sets the target price at $118.According to TipRanks data, the analyst has a
Morgan Stanley Initiates Structure Therapeutics at Overweight